Biotechnology

Standigm signs MOU with Institut Pasteur Korea for AI-based drug discovery research on infectious disease

SEOUL, South Korea, Nov. 30, 2021 /PRNewswire/ -- Standigm Inc. ("Standigm"), the leading workflow artificial intelligence (AI) drug discovery company, today announced the signing of a Memorandum of Understanding ("MOU") with Institut Pasteur Korea ("IPK"), the infectious disease-focused research...

2021-11-30 21:30 1446

Angel Yeast Enters Comprehensive Health Industry with New Joint Venture Project

YICHANG, China, Nov. 30, 2021 /PRNewswire/ -- Angel Yeast Co., Ltd ("Angel Yeast ")(en.angelyeast.com ), a listed high-tech yeast company inChina, has announced that it has signed an agreement with two prominent biomedical companies to establish a new joint venture, Hube...

2021-11-30 21:06 2509

Jemincare Announces the Exclusive License of the Kras Inhibitor to HUYABIO

SHANGHAI, Nov. 30, 2021 /PRNewswire/ -- Jemincare, a leading pharmaceutical company fromChina, announced today its wholly owned subsidiary company, Shanghai Jemincare Pharmaceutical Co., Ltd., had licensed exclusive worldwide ex-China rights to the Kras inhibitor, JMKX1899, to HUYABIO Internation...

2021-11-30 20:42 2067

Treadwell Therapeutics Announces US FDA Clearance of IND Application for Phase 2 Study of TTK inhibitor, CFI-402257

NEW YORK and HONG KONG, Nov. 30, 2021 /PRNewswire/ -- Treadwell Therapeutics, a clinical stage biotechnology company developing novel therapeutics for highly aggressive cancers, today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) applic...

2021-11-30 20:00 2258

ABM Therapeutics Receives IND Approval in China for BRAF Inhibitor ABM-1310

SAN DIEGO and SHANGHAI, Nov. 30, 2021 /PRNewswire/ -- ABM Therapeutics (ABM), a clinical-stage biopharmaceutical company with a focus on treating brain cancers and cancer metastases, today announced that its IND application for ABM-1310, a new-generation BRAF inhibitor, has been approved by the N...

2021-11-30 13:00 1491

GenScript ProBio, Abogen Biosciences and Walvax Biotechnology Enter into Collaboration on BLA and Commercial Manufacturing of mRNA Vaccine

NANJING, China and SINGAPORE, Nov. 30, 2021 /PRNewswire/ -- GenScript ProBio, Suzhou Abogen Biosciences Technology Co. ("Abogen Biosciences") and Walvax Biotechnology Co. ("Walvax Biotechnology") announced a collaboration on commercial manufacturing of a mRNA vaccine project ("ABO-028M"). Walvax ...

2021-11-30 10:39 2456

Sciwind Biosciences Acquires Global, Exclusive Rights to Develop and Commercialize Sanofi's GIP Receptor Agonists for the Treatment of Metabolic Disease

HANGZHOU, China and SAN FRANCISCO, Nov. 30, 2021 /PRNewswire/ -- Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat metabolic disease, announced today that it has signed a global, exclusive license agreemen...

2021-11-30 08:00 2781

SOPHiA GENETICS Hosts Symposium with GE Healthcare at RSNA 2021

Symposium to address how new AI-powered analytic and workflow solutions for clinical and biopharma markets are advancing data-driven medicine Symposium encapsulates SOPHiA GENETICS and GE Healthcare alliance to provide joint solutions and multimodal analytics to healthcare providers and biopharma...

2021-11-30 03:35 2105

CABIO receives USDA Organic certification for its Docosahexaenoic Acid Algae Oil Products

WUHAN, China, Nov. 29, 2021 /PRNewswire/ -- On November 18, 2021, CABIO Biotech (Wuhan) Co., Ltd ("CABIO") the first company commercializing ARA products in China received the notification from organic certification organization Ecocert SA that it has obtained USDA Organic certification for its D...

2021-11-29 21:45 1643

PharmaBlock Appointed Dr. Wenfang Miao as Chief Executive Officer

NANJING, China, Nov. 29, 2021 /PRNewswire/ -- PharmaBlock (300725.SZSE), an innovative chemistry products and services provider to support drug discovery, development, and commercialization, announced today that the former Senior Vice President of Quality, Dr.Wenfang Miao, is appointed as the com...

2021-11-29 20:00 1436

Ascentage Pharma Appoints Mr. Yiqing Chen as Chief Financial Officer

SUZHOU, China, and ROCKVILLE, MD., Nov. 29, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced the appointment of Mr.Yiqing Chen as Chief Financ...

2021-11-29 19:01 1978

Hummingbird Bioscience Appoints Jan Møller Mikkelsen as Chairman of the Board

HOUSTON and SINGAPORE, Nov. 29, 2021 /PRNewswire/ -- Hummingbird Bioscience Holdings Limited, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets in cancer and autoimmune disease, today announced the appointment of Jan Møller Mikkels...

2021-11-29 17:00 1762

Help Therapeutics Completes Series C Financing of 25 Million Dollars

NANJING, China, Nov. 29, 2021 /PRNewswire/ -- Recently, the iPSC therapeutics leading global platform company -Help Therapeutics announced the completion of Series C financing of 25 millions of dollars. This round of financing was led by Ming Bioventures, followed by Share Capital, Beisen Medical...

2021-11-29 16:25 1395

Tigermed Recognized with Frost & Sullivan 2021 China Clinical CRO Competitive Strategy Leadership Award

HANGZHOU, China, Nov. 29, 2021 /PRNewswire/ -- Tigermed, a leading provider of innovative clinical research solutions for biopharmaceutical and medical device industry, announced that it has been awarded the Frost & Sullivan 2021 China Contract Research Organization (CRO) Competitive Strategy Lea...

2021-11-29 15:27 1905

Australian biotech company Starpharma announces positive interim results from the prostate cancer cohort in its ongoing phase 2 trial of DEP® cabazitaxel

MELBOURNE, Australia, Nov. 26, 2021 /PRNewswire/ -- Starpharma showed that 100% of evaluable patients with Stage IV prostate cancer have had efficacy responses, utilising one or more standard measures of disease. DEP® cabazitaxel  is a patent...

2021-11-26 17:34 2721

Starpharma releases positive DEP® phase 2 interim results in prostate cancer

MELBOURNE, Australia, Nov. 26, 2021 /PRNewswire/ -- Melbourne biotech company Starpharma today announced positive interim results from the prostate cancer cohort in its ongoing phase 2 trial of DEP® cabazitaxel. The company showed that 100% of evaluable patients with (Stage IV) metastatic prostat...

2021-11-26 15:41 2049

Antengene Included in the MSCI Global Small Cap Indexes - MSCI China Index Constituent Stocks

SHANGHAI and HONG KONG, Nov. 26, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and onco...

2021-11-26 11:34 3681

Henlius Novel Anti PD-L1/TIGIT Bispecific Antibody Received Clinical Trial Approval in Australia

SHANGHAI, Nov. 25, 2021 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that the filing of a clinical trial for HLX301, a Recombinant Humanized Anti-PDL1 and Anti-TIGIT Bispecific Antibody, in Patients with locally advanced or metastatic solid tumours has been approved by the ...

2021-11-25 17:27 2973

Innovative €250,000 Parenteral Nutrition Research Grant Awarded by Fresenius Kabi

BAD HOMBURG, Germany, Nov. 25, 2021 /PRNewswire/ -- Fresenius Kabi was delighted to announce the winner of their innovative JUMPstart education program and research grant onSeptember 10, 2021. JUMPstart is an initiative that aims to nurture research in the field of parenteral nutrition through th...

2021-11-25 15:45 2676

Global Cord Blood Corporation Reports Financial Results for the Second Quarter and First Half of Fiscal 2022

Added 19,066 New Subscribers in 2Q22 Revenues Up 9.8% YoY to RMB313.7 Million ($48.7 Million)         Gross Profit Up 11.0% YoY to RMB267.5 Million ($41.5 Million) Operating Income Up 15.3% YoY to RMB160.5 Million ($24.9 Million) Non-GAAP Operating Income Up 14.1% YoY to RMB172.8 Million ($26.8 Mi...

2021-11-25 05:16 3754
1 ... 169170171172173174175 ... 281